Inicio › Leucemia linfocítica crónica › Washington

Ensayos clínicos de Leucemia linfocítica crónica en Washington

27 estudios sobre Leucemia linfocítica crónica buscan participantes en Washington.

Ciudades en Washington

Texto oficial del estudio (inglés)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

FHCC Overlake, Bellevue
Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04269902

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Medical Oncology Associates - Spokane, Spokane

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07342478

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Vista Oncology ( Site 5449), Olympia
Medical Oncology Associates, PS ( Site 5406), Spokane

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05947851

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Providence Regional Cancer System-Aberdeen, Aberdeen
PeaceHealth Saint Joseph Medical Center, Bellingham
Providence Regional Cancer System-Centralia, Centralia
y 20 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Swedish Cancer Institute-Edmonds, Edmonds
Swedish Medical Center-First Hill, Seattle

ReclutandoFase 3

Edades de 65 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07321652

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Fred Hutchinson Cancer Center, Seattle

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07221500

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06839053

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

ReclutandoFase 2

Edades de 18 a 80 · Todos los sexos · Actualizado el 30 oct 2026 · NCT06520098

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT07194980

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Fred Hutchinson Cancer Research Center, Seattle

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06697184

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutch/University of Washington Cancer Consortium, Seattle

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT04941716

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06943872

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Fred Hutch Cancer Center, Seattle

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT06528301

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Fred Hutchinson Cancer Research Center, Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Swedish Cancer Institute, Edmonds Campus ( Site 0072), Edmonds
Swedish Cancer Institute, Issaquah Campus ( Site 0073), Issaquah
Swedish Medical Center-Swedish Cancer Institute ( Site 0071), Seattle
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06136559

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Fred Hutchinson Cancer Research Center, Seattle

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT05006716

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study Site 103, Tacoma

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07582432

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, Seattle

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Research Center, Seattle

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Fred Hutchinson Cancer Research Center, Seattle
Summit Cancer Centers, Spokane
Northwest Medical Specialties, Tacoma

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Medical Oncology Associates, PS, Spokane

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05254743

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutch/University of Washington Cancer Consortium, Seattle

ReclutandoFase 2Se aceptan voluntarios sanos

6 Months · Todos los sexos · Actualizado el 29 may 2026 · NCT04195633

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Vista Oncology - East Olympia /ID# 267337, Olympia
Northwest Medical Specialties Tacoma /ID# 266327, Tacoma

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Swedish Cancer Institute, Seattle

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Swedish Cancer Institute, Seattle

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

Fred Hutchinson Cancer Center, Seattle

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Swedish Cancer Institute, Seattle

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2025 · NCT05780034

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.